Want to financially support original, independent reporting like this in less than 15 seconds? You can! Just click the advertisement at the top of this article - no purchases or personal information sharing required

On November 2, 2026, the nonprofit Usona Institute reportedly submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PSIL201, its synthetic psilocybin candidate for major depressive disorder (MDD). First reported by Psychedelic Alpha, the unconfirmed filing — on which Usona declined to comment — immediately rattled investors in for-profit competitor Compass Pathways, with share prices dropping 28% in one day following the news. Just a day later, on November 3, Compass  announced during its quarterly update that it will complete its own FDA submission for COMP360 in treatment-resistant depression (TRD) within two weeks. 

Compass is targeting a commercial launch in the first half of 2027, pending FDA approval and Drug Enforcement Administration (DEA) rescheduling. While these back-to-back milestones bring synthetic psilocybin to the threshold of federal review, projections that COMP360 could cost $18,000 to $22,000 per dose highlight a stark reality across the mental health sector: regulatory clearance and real-world patient access remain separated by steep commercial, clinical, and financial hurdles.

The two frontrunners enter the regulatory home stretch with contrasting clinical datasets and business structures. Compass backs COMP360 with the largest randomized, double-blind clinical program in psilocybin history across two pivotal Phase 3 studies, COMP005 and COMP006. 

According to Compass's 26-week Phase 3 COMP006 readout, 39% of TRD participants in the 25-milligram arm achieved a “clinically meaningful reduction” that remained durable through week 26, compared to 25% of single-dose participants in COMP005. That still leaves roughly three in five trial participants without sustained relief, however. 

Usona, meanwhile, is pursuing a broader Major Depression Disorder (MDD) label following a 2023 Phase 2 trial of 104 adults comparing a single 25-milligram psilocybin dose against niacin, alongside its Phase 3 uAspire trial, for which topline results have not yet been publicly released.

Where the rivals diverge most sharply is on commercialization, capital structure, and pricing. Compass executives have indicated they intend to benchmark COMP360's annualized price to Johnson & Johnson's ketamine-derived nasal spray, Spravato, at roughly $50,000 to $65,000 per patient per year. Assuming an average regimen of three administrations annually, a single dose of COMP360 is projected to land between $18,000 and $22,000 before accounting for multi-hour clinical supervision fees — a pricing strategy already slated for scrutiny by the Institute for Clinical and Economic Review (ICER). Backed by an extensive patent estate and an established sales force, Compass is built to defend those margins.

Usona, operating as a 501(c)(3) medical research organization without Orange Book patent barriers, could theoretically undercut Compass with lower pricing and a wider MDD indication. However, the nonprofit currently lacks an active commercial sales force and would likely need a distribution partner to bring PSIL201 to market at scale. Usona was co-founded in 2014 by billionaire philanthropist Bill Linton, the founder and CEO of Fitchburg, Wisconsin-based life sciences reagent manufacturer Promega Corporation. While Usona's headquarters sits adjacent to Promega's campus and Linton has personally helped bankroll Usona alongside a circle of wealthy philanthropic donors, confusion over the exact financial relationship between the two organizations spilled into public view last week. 

In its original November 2 report on Usona's NDA, Psychedelic Alpha asserted that Linton had funneled money from Promega into Usona and that the nonprofit benefited directly from Promega's corporate cash flow. On November 3, the U.K.-based trade publication issued a formal correction after Usona clarified that Usona and Promega are entirely separate legal entities and that Promega's corporate profits have never been used to fund Usona's operations. Despite fierce commercial tensions across the sector, Usona recently convened rival developers – including Compass, AbbVie, and Otsuka — for a Models of Care Summit focused on clinical delivery.

Both submissions are moving at compressed speeds thanks to an aggressive federal pivot. On April 18, 2026, President Donald Trump signed an Executive Order directing the Department of Health and Human Services (HHS), the FDA, and the DEA to accelerate treatments for serious mental illness, establish Right to Try access for Schedule I compounds including ibogaine, and allocate at least $50 million in existing Advanced Research Projects Agency for Health (ARPA-H) funds to state psychedelic programs. Six days later, on April 24, the FDA announced that it had awarded Commissioner's National Priority Vouchers to three investigational serotonin-2A agonists: Compass's COMP360 for TRD, Usona's PSIL201 for MDD, and Transcend Therapeutics' methylone candidate TSND-201 for post-traumatic stress disorder (PTSD), which Otsuka recently finalized their acquisition of.

The priority voucher pilot, coupled with the June 2025 appointment of psychedelic research proponent and former Usona Chief Medical Officer Mike Davis as Center for Drug Evaluation and Research (CDER) Director, aims to compress standard 10-to-12-month FDA review timelines down to just one or two months — though it does not lower the agency's evidentiary bar.

“For the millions of people living with depression and PTSD who need more options, a new generation of psychedelics now under FDA review is huge,” a statement from clinic operator Nushama noted. “It is also a signal. With more than 100 clinical trials underway, this is only the beginning of a wave of FDA reviews for mental health indications, and this will be the first of many.”

Whether the U.S. mental healthcare system can absorb supervised psilocybin sessions remains an open question. Compass began laying groundwork in April 2024 through a research collaboration with Journey Clinical to study scalable therapist training and care delivery models.

“The demand is already here,” said Myriam Barthes, co-founder and CEO of Journey Clinical. “Patients want new options, and 95% of Journey Clinical providers have told us they want to offer new psychedelics to their patients. To meet that demand, Journey Clinical is growing its network and has been building toward this milestone for five years. We will be among the first to train clinicians and administer care, ready on day one.” However, that 95% figure reflects internal feedback from a self-selected network of ketamine-assisted psychotherapy providers, rather than readiness across the broader psychiatric workforce.

Larger healthcare systems are watching cautiously. During a November 5 third-quarter earnings call, Dave Bourdon, CEO of outpatient mental health giant LifeStance Health, which employs 8,863 clinicians and operates 25 Spravato sites nationwide, declined to comment on specific psychedelic candidates while noting that “there's still regulatory, payer reimbursement, and adoption hurdles that remain unresolved.” Still, Bourdon signaled that LifeStance is positioning its specialty footprint for future rollouts: “Having said that, we are monitoring the new psychedelics, new therapies that are coming out, and we have the ability to move faster if that's appropriate.” 

Simultaneously, psychologists petitioned the American Psychological Association in early November to establish a formal Division of Psychedelic Science and Practice to develop ethical and clinical competency frameworks, though the division would not grant licensure or prescriptive authority.

Even if the FDA clears PSIL201 or COMP360 in early 2027, high per-dose costs and strict Risk Evaluation and Mitigation Strategies (REMS) could bottleneck adoption. Writing in Psychedelics Today on November 4, Logan Davidson, Director of Policy & Advocacy at Veterans Exploring Treatment Solutions (VETS), argued that the decisive battles over patient access will unfold not at the FDA, but in state licensing board hearings, legislative committees, and insurance coverage reviews. If commercial payers balk at $18,000-to-$22,000 drug invoices plus facility and therapist monitoring costs, access could rapidly stratify along socioeconomic and geographic lines.

“Usona's submission joins a growing list of psychedelic therapies that are now close to an FDA decision,” said Melissa Lavasani, Founder and Executive Director of the Psychedelic Medicine Coalition (PMC) in an exclusive statement provided to Psychedelic State(s) of America. “That's real progress, but the hype phase is over, and approval and access are two very different things.”

“The next chapter is about the less glamorous work” Lavasani continued, “making sure these treatments actually reach patients, including people in rural communities and women, who too often face the steepest barriers to mental health care.”

“Republican leaders have anchored much of this movement's progress in Washington alongside the veteran community,” she concluded “and with Democrats taking control of Congress in January, we have a chance to grow the coalition. Durable federal policy gets built when this work belongs to everyone.”

Founder’s Note: Psychedelic State(s) of America is committed to fostering rigorously diverse debate and discourse on all psychedelics-related topics.

While PSA publishes a broad range of commentary and opinion pieces as part of our broader content offerings, that does not mean that PSA team members agree with every perspective published on our site.

We welcome feedback and input on our editorial process, as well as submissions for consideration to be featured in PSA's Sunday Sound-Off series.

For feedback, submissions, and more information, contact PSA Founder Jack Gorsline at [email protected] 24/7/365.

Until next time,

The Psychedelic State(s) of America Team